SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

中文翻译：

---

参加合作组 2 期临床试验的复发或进展性尤文肉瘤患者的结果：来自儿童肿瘤组的报告

SevenChildren's Oncology Group 对复发/进展性实体瘤患者进行的 2 期试验进行了分析，以估计复发/进展性尤文肉瘤的无事件生存期 (EFS)。登记了 128 名尤文肉瘤患者，发生了 124 起事件。6 个月的 EFS 为 12.7%，表明这些患者的预后不佳。只有多西紫杉醇达到了方案规定的活性放射学反应率；然而，多西紫杉醇的 EFS 与其他药物相似，表明更高的放射学反应率可能不会转化为更好的疾病控制。该 EFS 基准可用作复发性尤文肉瘤试验的附加终点。